AnaptysBio (ANAB) Competitors $23.60 -0.37 (-1.54%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, and AAPGShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Lyell Immunopharma Apellis Pharmaceuticals Organon & Co. HUTCHMED ImmunityBio Amneal Pharmaceuticals Xenon Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International Lyell Immunopharma (NASDAQ:LYEL) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking. Does the media prefer LYEL or ANAB? In the previous week, AnaptysBio had 10 more articles in the media than Lyell Immunopharma. MarketBeat recorded 17 mentions for AnaptysBio and 7 mentions for Lyell Immunopharma. AnaptysBio's average media sentiment score of 0.68 beat Lyell Immunopharma's score of 0.44 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 4 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in LYEL or ANAB? 66.1% of Lyell Immunopharma shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by company insiders. Comparatively, 33.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, LYEL or ANAB? Lyell Immunopharma has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Is LYEL or ANAB more profitable? AnaptysBio has a net margin of -289.75% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% AnaptysBio -289.75%-287.94%-37.25% Which has higher earnings & valuation, LYEL or ANAB? AnaptysBio has higher revenue and earnings than Lyell Immunopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$65K2,460.41-$234.63M-$25.00-0.43AnaptysBio$111.87M6.30-$163.62M-$4.85-4.94 Do analysts rate LYEL or ANAB? Lyell Immunopharma currently has a consensus price target of $20.00, suggesting a potential upside of 85.19%. AnaptysBio has a consensus price target of $42.38, suggesting a potential upside of 76.78%. Given Lyell Immunopharma's higher probable upside, equities analysts clearly believe Lyell Immunopharma is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the MarketBeat Community prefer LYEL or ANAB? AnaptysBio received 366 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 66.55% of users gave AnaptysBio an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1443.75% Underperform Votes1856.25% AnaptysBioOutperform Votes38066.55% Underperform Votes19133.45% SummaryAnaptysBio beats Lyell Immunopharma on 13 of the 18 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$704.24M$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-3.948.7927.2120.17Price / Sales6.30263.51414.99161.94Price / CashN/A65.8538.2534.64Price / Book7.226.677.124.72Net Income-$163.62M$143.49M$3.23B$247.80M7 Day Performance12.69%5.15%3.80%2.76%1 Month Performance22.36%15.43%13.40%9.71%1 Year Performance1.35%6.02%32.04%14.51% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio1.9588 of 5 stars$23.60-1.5%$42.38+79.6%+1.5%$693.22M$111.87M-3.88100LYELLyell Immunopharma2.1802 of 5 stars$8.22-5.9%$1.00-87.8%-77.1%$2.43B$65,000.00-10.40270High Trading VolumeAPLSApellis Pharmaceuticals4.6571 of 5 stars$19.14+13.1%$40.05+109.3%-53.0%$2.41B$775.84M-9.43770Analyst RevisionHigh Trading VolumeOGNOrganon & Co.4.9261 of 5 stars$9.22-0.1%$18.00+95.3%-51.5%$2.40B$6.29B2.7710,000Trending NewsHCMHUTCHMED1.2799 of 5 stars$13.60-2.1%$19.00+39.7%-6.9%$2.37B$630.20M0.001,760Upcoming EarningsIBRXImmunityBio1.9585 of 5 stars$2.67+0.4%$12.25+358.8%-46.5%$2.36B$31.22M-2.90590High Trading VolumeAMRXAmneal Pharmaceuticals3.716 of 5 stars$7.42+1.4%$11.50+55.0%+14.0%$2.33B$2.83B-10.917,600Positive NewsXENEXenon Pharmaceuticals3.4792 of 5 stars$30.07+4.2%$54.82+82.3%-15.9%$2.31B$7.50M-10.66210Analyst RevisionMIRMMirum Pharmaceuticals2.9102 of 5 stars$45.97+3.4%$60.73+32.1%+91.7%$2.28B$379.25M-22.76140Positive NewsAnalyst RevisionARWRArrowhead Pharmaceuticals3.7308 of 5 stars$16.40+2.1%$42.13+156.9%-30.8%$2.26B$545.21M-3.17400Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600 Related Companies and Tools Related Companies Lyell Immunopharma Competitors Apellis Pharmaceuticals Competitors Organon & Co. Competitors HUTCHMED Competitors ImmunityBio Competitors Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANAB Stock Free ANAB Stock Alerts